|Bid||45.21 x 1100|
|Ask||45.45 x 1400|
|Day's Range||44.13 - 46.20|
|52 Week Range||9.64 - 84.49|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.25|
To help you invest better, we ask five Motley Fool contributors for their best ideas each month. For April, they came back with Netflix (NASDAQ: NFLX), Zillow Group (NASDAQ: Z)(NASDAQ: ZG), Axon Enterprise (NASDAQ: AXON), DermTech (NASDAQ: DMTK), and Clearway Energy (NYSE: CWEN)(NYSE: CWEN.A).
Last year, the growth stocks in the Nasdaq-100 index trounced the staid giants in the Dow Jones Industrial Average. DermTech (NASDAQ: DMTK) markets an exciting product: a skin genomics test that can detect melanoma more accurately and cheaper than surgical biopsy. Part of the problem was the aforementioned general sell-off of growth stocks.
DermTech (NASDAQ: DMTK) is trading well off its 52-week high of $84.49 per share while investors try to figure out how to value the prospects of the dermatology company. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights talk about what the company is doing to grow sales of its melanoma test and why the recent decline shouldn't be a big concern for long-term investors. Brian Orelli: Max asks, any info or thoughts on DermTech following and its prospects, bought it a high valuation and think they are creating fantastic products, so the sell-off is a little disconcerting.